UTIBRON NEOHALER (indacaterol/glycopyrrolate) Patient Assistance Program
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Utibron Neohaler (indacaterol 27.5 mcg/glycopyrrolate 15.6 mcg per capsule) is FDA-approved for the long-term, twice-daily maintenance treatment of airflow obstruction in patients with COPD. It is a fixed-dose combination of a LABA (indacaterol) and LAMA (glycopyrrolate) delivered via the Neohaler dry-powder inhaler.
- Without assistance, Utibron Neohaler costs commonly run approximately $500–$650 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Utibron Neohaler for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Utibron Neohaler in the U.S. as of 2026. Other LABA/LAMA combination inhalers include Anoro Ellipta (umeclidinium/vilanterol, once daily), Stiolto Respimat (tiotropium/olodaterol, once daily), Bevespi Aerosphere (glycopyrrolate/formoterol, twice daily), and Duaklir Pressair (aclidinium/formoterol, twice daily). Triple-therapy single inhalers (Trelegy, Breztri) add an ICS to the LABA/LAMA combination.
What Is Utibron Neohaler Prescription Assistance Program?
The Utibron Neohaler Prescription Assistance Program is a manufacturer-sponsored initiative that provides Utibron at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for COPD patients who are uninsured or underinsured.
Navigating the program on your own means dealing with eligibility verification, pulmonology/primary care coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, Utibron Neohaler costs roughly $500–$650/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$620 | Save ~$550/mo |
| CVS Pharmacy | ~$650 | Save ~$580/mo |
| Walmart | ~$540 | Save ~$470/mo |
| Costco | ~$520 | Save ~$450/mo |
Kroger | ~$530 | Save ~$460/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Utibron NeohalerPrescription Program?
The Patient Assistance Program is free to apply for and provides Utibron Neohaler at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Utibron Neohaler:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $500–$650 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Utibron Neohaler assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Utibron Neohaler Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured Or Underinsured And Cannot Afford Your Medication
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Utibron Neohaler:
Utibron Neohaler is a twice-daily fixed-dose combination LABA/LAMA inhaler used for COPD maintenance therapy. The combination of indacaterol (LABA) and glycopyrrolate (LAMA) provides dual bronchodilation through complementary mechanisms — beta2-mediated smooth muscle relaxation and cholinergic-receptor blockade.
How Utibron Neohaler Works:
Utibron combines indacaterol (a LABA) and glycopyrrolate (a LAMA) to target the two reversible components of COPD bronchoconstriction. By working through complementary pathways, this combination provides dual bronchodilation that improves lung function, reduces symptoms, and decreases exacerbation rates better than either drug alone. Delivered twice daily via the Neohaler dry-powder inhaler, it ensures continuous 24-hour bronchodilation. Proper delivery of the medication relies on the patient’s ability to produce an effective inspiratory flow during inhalation.
Form and use:
Utibron Neohaler is used as a long-term maintenance treatment for COPD and should not be used to treat acute symptoms. To use it, one capsule is loaded into the Neohaler device, pierced, and inhaled twice daily with a deep, strong breath. It is important to note that the capsules are designed for inhalation only and must never be swallowed. Patients are advised to rinse their mouth with water after each use to help reduce dry mouth.
Generic availability:
As of 2026, there is no generic version of Utibron Neohaler available in the U.S. Patients looking for alternatives have access to other brand-name LABA/LAMA combinations, such as Anoro Ellipta, Stiolto Respimat, Bevespi Aerosphere, Duaklir Pressair, and Spiolto/Yuvaltis, which vary by dosing frequency and device type. For patients experiencing frequent exacerbations, triple therapy options like Trelegy Ellipta or Breztri Aerosphere are available, which add an inhaled corticosteroid (ICS) to the mixture.
Warnings:
Utibron Neohaler is strictly for COPD and carries a warning regarding asthma-related death when LABAs are used as monotherapy for asthma. It can cause serious side effects, including paradoxical bronchospasm, cardiovascular changes like tachycardia and arrhythmias, worsening of narrow-angle glaucoma, and worsening of urinary retention. It may also lead to metabolic shifts like hypokalemia and hyperglycemia. Additionally, because the capsules contain lactose, there is a risk of bronchospasm for individuals with a milk-protein hypersensitivity.
FAQ (Frequently Asked Questions)
How Much Does Utibron Neohaler Cost Without Insurance?
Utibron Neohaler costs approximately $500–$650 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Utibron at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Utibron Different From Anoro Ellipta?
Both are LABA/LAMA combination inhalers for COPD. Utibron Neohaler (indacaterol/glycopyrrolate) is twice daily via dry-powder Neohaler device. Anoro Ellipta (umeclidinium/vilanterol) is once daily via dry-powder Ellipta inhaler. Both have similar efficacy. Once-daily dosing (Anoro, Stiolto Respimat) may improve adherence; twice-daily (Utibron, Bevespi, Duaklir) gives flexibility. Choice depends on dosing preference, inhaler-technique preference, and insurance coverage.
How Do I Use The Neohaler Device?
Open the inhaler. Place one capsule in the chamber. Close the inhaler. Press both side buttons firmly once to pierce the capsule (you should hear it crack). Breathe out away from the inhaler. Place the mouthpiece in your mouth, seal lips around it, and inhale rapidly and deeply — you should hear a whirring sound and feel a sweet taste (lactose). Hold breath ~5–10 seconds. Open the inhaler and discard the empty capsule. Rinse your mouth with water.
Is Utibron A Rescue Inhaler?
No. Utibron is a controller (maintenance) inhaler — not for acute symptoms. You should still have a separate short-acting rescue inhaler (typically albuterol) for sudden bronchospasm.
Should I Be On Triple Therapy Instead?
Depending on your COPD severity and exacerbation history, your pulmonologist may consider stepping up to triple therapy (LABA + LAMA + ICS in one inhaler — Trelegy Ellipta or Breztri Aerosphere) if you continue to have frequent exacerbations on dual LABA/LAMA. Triple therapy reduces exacerbations further but adds the ICS side-effect profile (pneumonia, oral thrush). Discuss with your prescriber if exacerbations remain frequent.
What About Drug Interactions?
Avoid concomitant use with other LABAs or LAMAs (don’t double up on either class). Caution with other anticholinergic agents (additive effects). Caution with QT-prolonging drugs or those that can cause hypokalemia (loop/thiazide diuretics, oral steroids), or in patients with conditions that prolong QT.
What If My Application Is Denied?
If denied, we explore alternatives — switching to another LABA/LAMA combination with its own PAP (Anoro Ellipta, Stiolto Respimat, Bevespi Aerosphere), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the COPD Foundation, American Lung Association, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Utibron Neohaler, our team may be able to help you access assistance programs designed to make brand LABA/LAMA combination inhaler therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.